| Project/Area Number |
06670591
|
|---|
| Research Category |
Grant-in-Aid for General Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Gastroenterology
|
|---|
| Research Institution | Kansai Medical University |
|---|
Principal Investigator |
NAITOH Yuji Kansai Medical University Assistant Professor, 医学部, 講師 (30198014)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TOSHIHITO Seki Kansai Medical University Assistant Professor, 医学部, 講師 (70163087)
城 知宏 関西医科大学, 医学部, 助手 (40257928)
|
|---|
| Project Period (FY) |
1994 – 1995
|
| Project Status |
Completed (Fiscal Year 1995)
|
| Budget Amount *help |
¥2,100,000 (Direct Cost: ¥2,100,000)
Fiscal Year 1995: ¥400,000 (Direct Cost: ¥400,000)
Fiscal Year 1994: ¥1,700,000 (Direct Cost: ¥1,700,000)
|
|---|
| Keywords | Integrin / Hepatocellular carcinoma / Cancer Metastasis / Inhibition of metastasis / Synthetic oligopeptide |
|---|
| Research Abstract |
(1) Expression of the integrins on hepatocellular carcinomas (HCCs) has been investigated by immumohistochemical and molecular biological technics. The constitutive integrins have been identified on the cell surface, and their expressions have been accompanied with gene expressions. Metastatic capacity of HCCs correlate well to the vascular invasiveness, staining patterns of AgNORs, and integrins which can bind extracellular matrices (ECM) present on the vascular endoetherial cells. Results obtained from these studies indicate that integrins expressed on highly metastatic HCCs may be clinical markers of distant metastasis, and useful indicators for evaluating the progress of HCC.
(2) Cultured human hepatoma cells exhibited the different patterns of adhesion to various ECM,depending on the expressions of integrins. Metastasis of HCCs have been effectively inhibited by cyclic oligopeptides in animal models. These results suggest that integrins expressed on the HCCs play an important role (s) in the cancer metastasis, and that oligopeptides could be applied in the clinical prevention and therapy of cancer metastasis.
|
